{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T18:59:28Z","timestamp":1760295568538},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.ygyno.2009.04.031","type":"journal-article","created":{"date-parts":[[2009,5,18]],"date-time":"2009-05-18T08:17:56Z","timestamp":1242634676000},"page":"265-272","source":"Crossref","is-referenced-by-count":38,"title":["Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients"],"prefix":"10.1016","volume":"114","author":[{"given":"Li","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele C.","family":"Madigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FengHua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate I.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Beretov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippa M.","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2009.04.031_bib1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ygyno.2003.10.025","article-title":"Reproductive and dietary risk factors for epithelial ovarian cancer in China","volume":"92","author":"Zhang","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.04.031_bib2","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/01.AOG.0000220516.34053.48","article-title":"Diagnosis and management of epithelial ovarian cancer","volume":"107","author":"Bhoola","year":"2006","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2009.04.031_bib3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nrc1611","article-title":"Ovarian cancer metastasis: integrating insights from disparate model organisms","volume":"5","author":"Naora","year":"2005","journal-title":"Nature Rev. Cancer"},{"key":"10.1016\/j.ygyno.2009.04.031_bib4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/1381612043453559","article-title":"The urokinase plasminogen activator system: role in malignancy","volume":"10","author":"Duffy","year":"2004","journal-title":"Curr. Pharm. Design"},{"key":"10.1016\/j.ygyno.2009.04.031_bib5","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1054\/fipr.2000.0079","article-title":"The urokinase plasminogen activation system as a novel target for tumour therapy","volume":"14","author":"Schmitt","year":"2000","journal-title":"Fibrinol. & Proteol."},{"key":"10.1016\/j.ygyno.2009.04.031_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2867-5-1","article-title":"Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity","volume":"5","author":"Morgan","year":"2005","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ygyno.2009.04.031_bib7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1023\/A:1023099415940","article-title":"The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy","volume":"22","author":"Sidenius","year":"2003","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ygyno.2009.04.031_bib8","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/0959-8049(94)90178-3","article-title":"Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer","volume":"30","author":"Casslen","year":"1994","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2009.04.031_bib9","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/(SICI)1097-0215(19961220)69:6<475::AID-IJC10>3.0.CO;2-0","article-title":"Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors","volume":"69","author":"van der Burg","year":"1996","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2009.04.031_bib10","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1038\/sj.bjc.6690278","article-title":"Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc","volume":"79","author":"Kuhn","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2009.04.031_bib11","first-page":"1743","article-title":"Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer","volume":"7","author":"Konecny","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2009.04.031_bib12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/ijc.1215","article-title":"Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1)","volume":"92","author":"Borgfeldt","year":"2001","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2009.04.031_bib13","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/ijc.11420","article-title":"High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer","volume":"107","author":"Borgfeldt","year":"2003","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2009.04.031_bib14","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1600-0463.2006.apm_298.x","article-title":"Prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) in Danish patients with recurrent epithelial ovarian cancer (REOC)","volume":"114","author":"Begum","year":"2006","journal-title":"APMIS"},{"key":"10.1016\/j.ygyno.2009.04.031_bib15","first-page":"125","article-title":"Announcement, FIGO stages 1988. Revisions","volume":"5","author":"Creasman","year":"1989","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.04.031_bib16","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.ygyno.2003.11.055","article-title":"Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer","volume":"92","author":"Seo","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.04.031_bib17","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.humpath.2006.05.002","article-title":"Expression of urokinase plasminogen activator (uPA) and its receptor (uPAR) in the progression of prostate cancer: potential therapeutic targets","volume":"37","author":"Cozzi","year":"2006","journal-title":"Human. Pathol."},{"key":"10.1016\/j.ygyno.2009.04.031_bib18","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0046-8177(95)90276-7","article-title":"Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness","volume":"26","author":"Buo","year":"1995","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ygyno.2009.04.031_bib19","first-page":"636","article-title":"The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients","volume":"60","author":"Foekens","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2009.04.031_bib20","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/(SICI)1097-0215(19981218)79:6<588::AID-IJC6>3.0.CO;2-W","article-title":"High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of uPA mRNA in poorly differentiated serous ovarian carcinoma","volume":"79","author":"Borgfeldt","year":"1998","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2009.04.031_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z","article-title":"The urokinase-type plasminogen activator system in cancer metastasis: a review","volume":"72","author":"Andreasen","year":"1997","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2009.04.031_bib22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1055\/s-0038-1657541","article-title":"Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy","volume":"78","author":"Schmitt","year":"1997","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ygyno.2009.04.031_bib23","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1083\/jcb.144.6.1285","article-title":"A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling","volume":"144","author":"Wei","year":"1999","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ygyno.2009.04.031_bib24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s000180050497","article-title":"The plasminogen activation system in tumor growth, invasion, and metastasis","volume":"57","author":"Andreasen","year":"2000","journal-title":"Cell Mol. Life Sc."},{"key":"10.1016\/j.ygyno.2009.04.031_bib25","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1160\/TH06-11-0669","article-title":"uPAR\u2013uPA\u2013PAI-1 interactions and signaling: a vascular biologist's view","volume":"97","author":"Binder","year":"2007","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ygyno.2009.04.031_bib26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/jcp.10142","article-title":"New insights into the role of extracellular matrix during tumor onset and progression","volume":"192","author":"Pupa","year":"2002","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.ygyno.2009.04.031_bib27","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.bbrc.2008.03.038","article-title":"Urokinase directly activates matrix metalloproteinases-9: a potential role in glioblastoma invasion","volume":"369","author":"Zhao","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ygyno.2009.04.031_bib28","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1158\/1078-0432.CCR-06-2088","article-title":"Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis","volume":"13","author":"He","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2009.04.031_bib29","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1158\/0008-5472.CAN-04-1800","article-title":"Proinvasive properties of ovarian cancer ascites-derived membrane vesicles","volume":"64","author":"Graves","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2009.04.031_bib30","first-page":"2396","article-title":"Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer","volume":"7","author":"Schmalfeldt","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2009.04.031_bib31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrc745","article-title":"New functions for the matrix metalloproteinases in cancer progression","volume":"2","author":"Egeblad","year":"2002","journal-title":"Nat. Rev."},{"key":"10.1016\/j.ygyno.2009.04.031_bib32","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1158\/1078-0432.CCR-05-2338","article-title":"The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer","volume":"12","author":"Kamat","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2009.04.031_bib33","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1309\/49LA9XCBGWJ8F2KM","article-title":"Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer","volume":"129","author":"Perigny","year":"2008","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ygyno.2009.04.031_bib34","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ygyno.2003.11.011","article-title":"Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression","volume":"92","author":"Trong","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.04.031_bib35","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/mc.20273","article-title":"Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis","volume":"46","author":"Cai","year":"2007","journal-title":"Mol. Carcinogenesis"},{"key":"10.1016\/j.ygyno.2009.04.031_bib36","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1200\/JCO.2001.19.15.3447","article-title":"Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial","volume":"19","author":"Bramhall","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.04.031_bib37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1023\/A:1023047431869","article-title":"Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials","volume":"22","author":"Pavlaki","year":"2003","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ygyno.2009.04.031_bib38","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1200\/JCO.2001.19.15.3445","article-title":"Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design","volume":"19","author":"Hess","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.04.031_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00262-007-0365-5","article-title":"Anti-cancer therapies targeting the tumor stroma","volume":"57","author":"Hofmeister","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ygyno.2009.04.031_bib40","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.canlet.2005.03.060","article-title":"Cytotoxicity of PAI2, C595 and herceptin vectors labeled with the alpha-emitting radioisotope bismuth-213 for ovarian cancer cell monolayers and clusters","volume":"234","author":"Song","year":"2006","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ygyno.2009.04.031_bib41","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ygyno.2005.05.023","article-title":"A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial","volume":"99","author":"Berkenblit","year":"2005","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809002832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809002832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T05:16:58Z","timestamp":1558329418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825809002832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0090825809002832"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2009.04.031","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}